| symbol |
TWST |
|---|
| 会社名 | Twist Bioscience Corp （ツイスト・バイオサイエンス） |
|---|
| 分野（sector） |
|
|---|
| 産業（industry） |
|
|---|
| 業種 |
医薬品
医療関連（Health Care）
|
|---|
| 概要 |
Twist Bioscience Corporation is a synthetic biology company. The Company is developing a disruptive deoxyribonucleic acid (DNA) synthesis platform to industrialize the engineering of biology. The Company has a semiconductor-based synthetic DNA manufacturing process featuring 10000-well silicon platform which is capable of producing synthetic biology tools such as genes oligonucleotide pools and variant libraries. Its silicon-based DNA writing platform offers synthesis of genes on silicon. Its products include clonal perfect genes and non-clonal fragments. It offers protein scanning single variant libraries. Its design methodology coupled with its silicon-based synthesis platform enables synthesis of each library variant positioned exactly where user wants it to be. It offers unamplified oligo pools and cloning-ready oligo pools. Its platform offers synthesis of oligonucleotide pools for specific targeting. ツイスト・バイオサイエンスは米国のバイオテクノロジー企業。主にDNA合成による製品の製造・販売に従事。独自プラットフォームによりDNA合成の効率化を実現し、合成遺伝子、試薬調製用ツール、創薬のための抗体ライブラリのほか、デジタルデータ記憶媒体としての合成DNA製品を提供する。本社所在地はカリフォルニア州サンフランシスコ。
|
|---|
| 本社所在地 | 455 Mission Bay Boulevard South Suite 545 San Francisco CA 94158 USA |
|---|
| 代表者氏名 | Emily M. Leproust エミリー・M・レプルースト |
|---|
| 代表者役職名 | President Chief Executive Officer Director 代表取締役社長 |
|---|
| 電話番号 | +1 408-410-0105 |
|---|
| 設立年月日 | 41306 |
|---|
| 市場名 | NASDAQ National Market System |
|---|
| ipoyear | 年 |
|---|
| 従業員数 | 289人 |
|---|
| url | :www.twistbioscience.com |
|---|
| nasdaq_url | |
|---|
| adr_tso | |
|---|
| EBITDA | |
|---|
| 終値（lastsale） | |
|---|
| 時価総額（marketcap） | |
|---|
| 時価総額 | |
|---|
| 売上高 | |
|---|
| 企業価値(EV) | |
|---|
| 当期純利益 | |
|---|
| 決算概要 | BRIEF: For the six months ended 31 March 2019 Twist Bioscience Corp revenues increased from $10.5M to $25M. Net loss increased 44% to $48.6M. Revenues reflect United States segment increase from $4.4M to $17.9M EMEA segment increase from $1.4M to $5.7M. Higher net loss reflects Interest expense increase of 17% to $688K (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$1.27 to -$2.11. |
|---|